1. Home
  2. CCAP vs PHAR Comparison

CCAP vs PHAR Comparison

Compare CCAP & PHAR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • CCAP
  • PHAR
  • Stock Information
  • Founded
  • CCAP 2015
  • PHAR 1988
  • Country
  • CCAP United States
  • PHAR Netherlands
  • Employees
  • CCAP N/A
  • PHAR N/A
  • Industry
  • CCAP Finance: Consumer Services
  • PHAR Biotechnology: Pharmaceutical Preparations
  • Sector
  • CCAP Finance
  • PHAR Health Care
  • Exchange
  • CCAP Nasdaq
  • PHAR Nasdaq
  • Market Cap
  • CCAP 732.0M
  • PHAR 618.3M
  • IPO Year
  • CCAP N/A
  • PHAR N/A
  • Fundamental
  • Price
  • CCAP $19.60
  • PHAR $8.76
  • Analyst Decision
  • CCAP Buy
  • PHAR Strong Buy
  • Analyst Count
  • CCAP 6
  • PHAR 3
  • Target Price
  • CCAP $19.33
  • PHAR $27.00
  • AVG Volume (30 Days)
  • CCAP 81.2K
  • PHAR 5.6K
  • Earning Date
  • CCAP 02-19-2025
  • PHAR 03-13-2025
  • Dividend Yield
  • CCAP 10.41%
  • PHAR N/A
  • EPS Growth
  • CCAP 57.74
  • PHAR N/A
  • EPS
  • CCAP 2.55
  • PHAR N/A
  • Revenue
  • CCAP $200,903,000.00
  • PHAR $285,745,000.00
  • Revenue This Year
  • CCAP $9.80
  • PHAR $20.08
  • Revenue Next Year
  • CCAP N/A
  • PHAR $9.22
  • P/E Ratio
  • CCAP $7.69
  • PHAR N/A
  • Revenue Growth
  • CCAP 19.05
  • PHAR 30.64
  • 52 Week Low
  • CCAP $15.91
  • PHAR $6.65
  • 52 Week High
  • CCAP $20.03
  • PHAR $13.20
  • Technical
  • Relative Strength Index (RSI)
  • CCAP 56.25
  • PHAR 42.64
  • Support Level
  • CCAP $19.10
  • PHAR $8.49
  • Resistance Level
  • CCAP $19.57
  • PHAR $9.57
  • Average True Range (ATR)
  • CCAP 0.29
  • PHAR 0.57
  • MACD
  • CCAP 0.03
  • PHAR -0.14
  • Stochastic Oscillator
  • CCAP 91.55
  • PHAR 16.27

About CCAP Crescent Capital BDC Inc. Common stock

Crescent Capital BDC Inc is a business development company structured as an externally managed, closed-end, non-diversified management investment company. The company's primary investment objective is to maximize the total return to its stockholders in the form of current income and capital appreciation through debt and related equity investments. It will seek to achieve its investment objectives by investing in secured debt (including senior secured, unitranche, and second lien debt) and unsecured debt (including senior unsecured, mezzanine, and subordinated debt), as well as related equity securities of private U.S. middle-market companies.

About PHAR Pharming Group N.V.

Pharming Group is a global biopharmaceutical company dedicated to transforming the lives of patients with rare, debilitating, and life-threatening diseases. It is commercializing and developing an innovative portfolio of protein replacement therapies and precision medicines to serve the unserved rare disease patients. Its product includes Ruconest. The revenue is generated from the United States.

Share on Social Networks: